Abstract |
Leukemia represents the most common pediatric malignancy, accounting for approximately 30% of all cancers in children less than 20 years of age. Most children diagnosed with leukemia are cured without hematopoietic stem cell transplantation (HSCT), but for some high-risk subgroups, allogeneic HSCT plays an important role in their therapeutic approach. The characteristics of these high-risk subgroups and the role of HSCT in childhood leukemias are discussed.
|
Authors | Alan S Wayne, Kristin Baird, R Maarten Egeler |
Journal | Pediatric clinics of North America
(Pediatr Clin North Am)
Vol. 57
Issue 1
Pg. 1-25
(Feb 2010)
ISSN: 1557-8240 [Electronic] United States |
PMID | 20307709
(Publication Type: Journal Article, Review)
|
Copyright | Copyright 2010 Elsevier Inc. All rights reserved. |
Topics |
- Global Health
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Leukemia
(mortality, surgery)
- Survival Rate
(trends)
- Treatment Outcome
|